peptide garden
Menu
Peptide Profile

CJC-1295

CJC-1295 (DAC:GRF)

A synthetic GHRH analog designed for sustained growth hormone elevation. Phase I data confirms activity; clinical development halted after a participant death in 2006.

Reviewed March 2026·16 min read·11 citations·Research compoundNot FDA-approved

Regulatory update: February 2026

CJC-1295 was removed from Category 2 in September 2024 and is expected to be reclassified to Category 1 under the Kennedy reclassification. The situation is complex — PCAC previously recommended against inclusion. Formal action is pending.

Updated March 17, 2026

On this page

At a glance

CJC-1295 is a synthetic long-acting analog of growth hormone-releasing hormone (GHRH). Phase I clinical data confirms it works as intended — producing sustained, dose-dependent elevations in growth hormone and IGF-1. But clinical development was permanently halted in 2006 after a participant died during a Phase II trial. The compound's developer, ConjuChem Biotechnologies, is now defunct, and no company is pursuing further development.

Animal studiesModerate~15 studies

Preclinical studies confirm GHRH receptor agonism and normalized growth in GHRH knockout mice. Fewer total studies than some peptides, but the mechanism is well-understood from decades of GHRH research.

Human evidenceLimited2 published trials

Phase I data (~60 participants) confirmed dose-dependent GH and IGF-1 elevation. Phase II (~80 participants) halted after a participant death. No Phase III trials have ever been conducted.

Safety dataLimited1 death during trial

Phase I showed good tolerability at studied doses. Phase II was terminated after a participant death from myocardial infarction, attributed to underlying coronary artery disease. No long-term safety data exists.

How are these scores calculated?

CJC-1295 demonstrably elevates growth hormone — Phase I data leaves little doubt about that. The unresolved questions are whether that elevation translates into meaningful clinical benefits, and whether the compound can be used safely long-term. The Phase II death and the absence of any ongoing development mean these questions may never be answered.

New research, delivered clearly

When new studies publish or clinical trials report results, we'll break them down in plain language.

Quick facts

Molecular weight
3,367.9 Da
Amino acids
30 (modified GHRH analog)
CAS Number
863288-34-0 (DAC) / 446036-97-1 (no DAC)
First described
2005 (ConjuChem, Montreal)
FDA status
Regulatory limbo (not Cat 1 or Cat 2)
WADA status
Prohibited (Section S2)

Amino acid sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(MPA)-NH2

What is CJC-1295?

CJC-1295 is a synthetic peptide designed to mimic your body's natural growth hormone-releasing hormone (GHRH) — the signal that tells your pituitary gland to produce and release growth hormone. What makes CJC-1295 different from natural GHRH is that it lasts dramatically longer in the body: days instead of minutes.[1]

The compound was developed by ConjuChem Biotechnologies, a Montreal-based biotech company, and first described scientifically in 2005. ConjuChem's innovation was a proprietary "Drug Affinity Complex" (DAC) — a chemical modification at the end of the peptide that allows it to bind to albumin (a protein in your blood), extending its half-life from minutes to approximately 6-8 days.

The critical distinction: with DAC vs. without DAC

When people discuss "CJC-1295," they may be talking about two related but pharmacologically distinct compounds:

  • CJC-1295 with DAC is the original compound tested in clinical trials. The DAC allows it to bind to albumin, producing sustained, continuous GH elevation over days. Half-life: 6-8 days.
  • CJC-1295 without DAC (also called Mod GRF 1-29 or Modified GRF 1-29) is the same peptide backbone without the albumin-binding modification. It has a much shorter half-life (~30 minutes) and produces pulsatile rather than continuous GH release.

This distinction matters because most community protocols use the version without DAC, reasoning that pulsatile GH release better mimics the body's natural pattern. But the published clinical trial data is exclusively on the version with DAC. They are not interchangeable, and evidence for one does not automatically apply to the other.

How it works

In simple terms, CJC-1295 tells your pituitary gland to make and release more growth hormone. It does this by binding to the same receptor as your body's natural GHRH signal — but because of its chemical modifications, it stays active for much longer than the natural hormone.[2]

The result is a sustained elevation of both growth hormone (GH) and IGF-1 (insulin-like growth factor 1, which GH stimulates your liver to produce). Importantly, Phase I data showed that GH secretion under CJC-1295 remains pulsatile — it comes in bursts rather than a steady stream — which preserves the body's natural rhythm.[3]

Detailed mechanism (for advanced readers)

CJC-1295's mechanism centers on GHRH receptor agonism with enhanced pharmacokinetics:

  • GHRH receptor binding: CJC-1295 binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both synthesis and pulsatile secretion of growth hormone.[4]
  • DPP-IV resistance: Four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) prevent enzymatic degradation by dipeptidylpeptidase-IV, which normally inactivates native GHRH within minutes.
  • Albumin binding (DAC version only): The maleimidopropionyl group at position 30 forms a covalent thioether bond with cysteine-34 on serum albumin, extending the circulating half-life to 5.8-8.1 days.[1]
  • Preserved pulsatility: Despite continuous receptor stimulation, GH secretion remains pulsatile — a key distinction from exogenous GH administration, which provides a non-physiologic steady state.[3]

How it differs from related compounds:

  • vs. Sermorelin: Sermorelin is a truncated native GHRH (amino acids 1-29) without modifications for DPP-IV resistance. Previously FDA-approved for pediatric GH deficiency (Geref, discontinued 2008 for supply reasons, not safety). Half-life: ~10-20 minutes. CJC-1295 is essentially an engineered, longer-lasting version of sermorelin.
  • vs. Tesamorelin (Egrifta): Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy. It is dosed daily; CJC-1295 with DAC could theoretically be dosed weekly.
  • vs. Ipamorelin: Ipamorelin is a ghrelin/GHSR agonist (growth hormone secretagogue), NOT a GHRH analog. It acts on a completely different receptor. CJC-1295 and ipamorelin are commonly stacked because they stimulate GH through complementary pathways.
  • vs. Exogenous GH (HGH): CJC-1295 stimulates your own GH production; exogenous GH bypasses pituitary regulation entirely. CJC-1295 preserves pulsatile release; exogenous GH does not.

What the research says

CJC-1295 works. Phase I data clearly shows it elevates growth hormone and IGF-1 in a sustained, dose-dependent manner. But working as a pharmacologic tool and working as a medicine are two very different things — and the Phase II trial that might have bridged that gap was halted after a participant died.

Peptide Garden evidence assessment, March 2026

Research timeline

CJC-1295 has a relatively brief research history — most of it concentrated in a single year — followed by complete abandonment of clinical development:

  1. 2005Preclinical

    CJC-1295 first described

    ConjuChem Biotechnologies publishes the foundational paper identifying CJC-1295 and the DAC albumin-binding technology. Rat studies demonstrate functional GHRH receptor agonism with extended duration.

  2. 2006Human study

    Phase I confirms GH elevation in humans

    Teichman et al. publish two Phase I studies in JCEM showing dose-dependent, sustained GH and IGF-1 elevation in healthy adults. Pulsatile GH secretion preserved. Well-tolerated at 30-60 mcg/kg.

  3. 2006Preclinical

    GHRH knockout mouse study

    Alba et al. at Johns Hopkins demonstrate that once-daily CJC-1295 normalizes growth in GHRH knockout mice, confirming functional agonism of the GHRH receptor in vivo.

  4. 2006Human study

    Phase II halted after participant death

    A participant in the Phase II HIV lipodystrophy trial dies from myocardial infarction approximately 3 hours after the 11th dose. The attending physician attributed the death to underlying asymptomatic coronary artery disease. ConjuChem permanently discontinues the trial and all CJC-1295 development.

  5. 2009Human study

    Serum protein profile analysis published

    Ionescu and Frohman publish proteomic analysis of Phase I participant sera, identifying potential biomarkers of GH/IGF-1 axis activation by CJC-1295.

  6. 2010Regulatory

    Anti-doping identification method published

    Henninge et al. publish a forensic method for identifying CJC-1295 in pharmaceutical preparations, supporting WADA's prohibition of the compound.

  7. 2023Regulatory

    FDA places CJC-1295 on Category 2 list

    The FDA classifies CJC-1295 as a Category 2 bulk drug substance, citing insufficient safety evidence. Compounding pharmacies can no longer legally prepare it.

  8. 2024Regulatory

    Removed from Category 2 — but not added to Category 1

    FDA removes CJC-1295 from Category 2 after the nominator withdraws. However, it is NOT added to Category 1 (permitting compounding). PCAC recommends against inclusion in the 503A Bulks list. CJC-1295 enters regulatory limbo.

  9. 2026Regulatory

    Kennedy reclassification announced

    HHS Secretary Kennedy announces CJC-1295 among peptides expected to return to legal compounding status. Formal FDA action still pending as of March 2026.

Human clinical trials

The published human evidence for CJC-1295 consists of two Phase I studies from the same research program and one halted Phase II trial. Here's what each found:

2006·Phase I, open-label, dose-escalation·n=60Moderate quality

Prolonged GH and IGF-I stimulation by CJC-1295 (single dose)

Healthy adults — pharmacokinetics

Single subcutaneous injection produced dose-dependent GH increases (2-10 fold for 6+ days) and IGF-1 increases (1.5-3 fold for 9-11 days). Well-tolerated at 30-60 mcg/kg. No serious adverse events.

2006·Phase I, multiple-dose extension·n=30Moderate quality

Pulsatile GH secretion persists during CJC-1295 stimulation (multiple dose)

Healthy adults — sustained dosing

Multiple weekly doses maintained elevated GH/IGF-1 for 28+ days. Pulsatile GH secretion preserved — an important finding suggesting CJC-1295 does not override the body's natural GH rhythm.

2006·Randomized, double-blind, placebo-controlled·n=80Low quality

Phase II in HIV lipodystrophy (halted after death)

HIV-associated visceral obesity

Trial permanently discontinued after one participant died from myocardial infarction ~3 hours after the 11th dose. Attending physician attributed death to underlying asymptomatic coronary artery disease. No efficacy results were ever published.

Both Phase I studies were published in the Journal of Clinical Endocrinology & Metabolism (JCEM) by Teichman et al.[2][3] The Phase II trial was registered as NCT00267527 but predated mandatory results reporting, and no data was ever published.[7]

About the Phase II death: This is the defining event in CJC-1295's history. A participant in the HIV lipodystrophy trial died from a myocardial infarction approximately 3 hours after receiving the 11th dose. The attending physician believed the death was caused by underlying, asymptomatic coronary artery disease — essentially a plaque rupture that would have happened regardless. ConjuChem permanently halted the trial and all CJC-1295 development. We cannot know with certainty whether CJC-1295 contributed to the event — but the observed vasodilatory effects and heart rate changes in Phase I participants mean cardiovascular effects cannot be fully ruled out.[8]

Animal studies

The preclinical evidence base for CJC-1295 is narrower than some peptides but mechanistically sound. The most important study demonstrated that once-daily CJC-1295 normalized body weight and length in GHRH knockout mice — animals genetically engineered to lack GHRH signaling — confirming that CJC-1295 functionally activates the GHRH receptor in vivo.[4]

CJC-1295's mechanism doesn't require extensive preclinical validation in the same way as a novel target would, because the GHRH-GH-IGF-1 axis is one of the most thoroughly studied hormonal pathways in endocrinology. The question was never whether a GHRH analog would elevate GH — it was whether the DAC technology could extend the duration of action. The Phase I data answered that question.

What the evidence shows

CJC-1295 is marketed for a range of benefits — from body recomposition to better sleep to anti-aging. Here's what the published research actually supports:

Does CJC-1295 increase growth hormone and IGF-1 levels?

Yes. Phase I human data clearly demonstrates dose-dependent, sustained GH elevation (2-10 fold) and IGF-1 elevation (1.5-3 fold) lasting days to weeks after a single injection. Pulsatile GH release is preserved. This is the strongest area of CJC-1295 evidence.

Well-supported

Can CJC-1295 improve body composition (more muscle, less fat)?

No human study has measured body composition outcomes with CJC-1295. The claim is extrapolated from GH/IGF-1 biology — growth hormone is known to promote lean mass and lipolysis — but no outcome trial was ever completed. The Phase II trial that might have answered this question was halted.

More research needed

Does CJC-1295 improve sleep quality?

Widely reported in online communities. Biologically plausible — growth hormone is naturally secreted in pulses during deep sleep, and augmenting GH release could theoretically enhance sleep architecture. However, no clinical study has measured sleep outcomes with CJC-1295.

More research needed

Does CJC-1295 have anti-aging effects?

No clinical data. Claims are based on the known biology of GH and IGF-1 in aging (declining GH with age, associations between IGF-1 and vitality). But the relationship between GH supplementation and healthy aging is itself controversial — some research suggests chronically elevated IGF-1 may increase cancer risk.

More research needed

Is CJC-1295 safe?

Phase I data at 30-60 mcg/kg showed good tolerability with mild side effects (injection site reactions, flushing, headache). However, the Phase II trial was halted after a participant death from myocardial infarction. While attributed to underlying disease, the event — combined with observed vasodilatory effects and heart rate changes — means cardiovascular safety is unresolved. No long-term safety data exists.

More research needed

Safety & side effects

The Phase II death

The most significant safety event in CJC-1295's history is a death during the Phase II clinical trial. A participant in a multi-site study of CJC-1295 for HIV-associated lipodystrophy died from myocardial infarction approximately 3 hours after receiving the 11th weekly dose. The attending physician attributed the death to underlying asymptomatic coronary artery disease with plaque rupture — essentially, a heart attack that could have happened at any time.[8]

However, it's important to note that the Phase I studies observed vasodilatory effects (flushing) and transient heart rate changes in participants. Whether CJC-1295 could have contributed to the cardiovascular event — perhaps by triggering hemodynamic stress in a patient with vulnerable plaque — is unknown. ConjuChem made the decision to permanently halt all development.

What Phase I showed

In the Phase I studies at doses of 30-60 mcg/kg, CJC-1295 was generally well-tolerated. Observed side effects included:[2]

  • Injection site reactions (redness, pain)
  • Transient flushing
  • Headache
  • Dizziness
  • No serious adverse events at the studied doses

Community-reported side effects

Among people who have used CJC-1295 (primarily the no-DAC version) outside of clinical settings, commonly reported effects include:

  • Water retention and bloating
  • Tingling or numbness in hands and fingers (carpal tunnel-like symptoms, consistent with elevated GH)
  • Increased hunger (especially when combined with ipamorelin)
  • Vivid dreams and disrupted sleep (especially the DAC version)
  • Flushing after injection
  • Fatigue and joint pain
  • Lightheadedness (more common at higher doses)

These are self-reported and not from controlled studies.

Theoretical risks

GH/IGF-1 excess and cancer risk: Chronic supraphysiologic GH and IGF-1 elevation carries established risks including insulin resistance, joint pain, and soft tissue swelling. More concerning, IGF-1 is a growth factor that may promote tumor growth — elevated IGF-1 has been associated with increased cancer risk in epidemiological studies. This is a class-wide concern for all GH-elevating compounds, not specific to CJC-1295.

Contraindications and interactions

Theoretical contraindications (based on mechanism of action, not clinical data):

  • Active cancer or history of cancer (IGF-1 elevation may promote tumor growth)
  • History of cardiovascular disease (given the Phase II trial event)
  • Diabetes or pre-diabetes (GH can worsen insulin resistance)
  • Active pituitary tumors
  • Pregnancy and breastfeeding (no safety data)

Drug interactions: No formal interaction studies in humans.

  • Insulin / diabetes medications: GH elevation can increase insulin resistance, potentially requiring medication adjustments
  • Corticosteroids: May blunt GH response
  • Anticoagulants: Theoretical interaction via hemodynamic effects

How people use it

CJC-1295 is most commonly discussed in the context of body composition optimization, anti-aging, and recovery. Here's what the landscape of use looks like — with important caveats.

The CJC-1295 / Ipamorelin stack

The most common community protocol pairs CJC-1295 (usually the no-DAC version) with ipamorelin, a ghrelin receptor agonist. The rationale: CJC-1295 stimulates GH release via the GHRH receptor, while ipamorelin stimulates it via the ghrelin receptor. These two pathways are synergistic — together, they amplify GH release beyond what either achieves alone.

Before the FDA's Category 2 classification in 2023, the CJC-1295/ipamorelin combination was one of the most commonly prescribed peptide protocols through telehealth and anti-aging clinics. It was often positioned as a "safer alternative to HGH."

Administration

  • Subcutaneous injection is the standard route for both versions
  • CJC-1295 with DAC: Typically discussed as weekly dosing (long half-life)
  • CJC-1295 without DAC (Mod GRF 1-29): Typically discussed as 1-3 times daily (short half-life), often before bed to coincide with the natural nocturnal GH pulse

About dosing information: Specific dosing ranges are not published on Peptide Garden pending legal review. No CJC-1295 dosing protocol has been validated in a human clinical trial for any clinical outcome. The Phase I trial used 30-60 mcg/kg as a single subcutaneous dose (with DAC). If you're considering CJC-1295, the right first step is a conversation with a knowledgeable healthcare provider.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

As of March 2026:

FDA status

CJC-1295 is not FDA-approved for any indication. Its regulatory history is unusually convoluted:

  • September 2023: FDA places CJC-1295 on the Category 2 list of bulk drug substances with safety concerns, prohibiting compounding.
  • September 2024: The nominator withdraws, and FDA removes CJC-1295 from Category 2.
  • December 2024: The Pharmacy Compounding Advisory Committee (PCAC) reviews CJC-1295 and recommends against including it in the 503A Bulks list (Category 1), which would permit compounding.
  • February 2026: HHS Secretary Kennedy announces CJC-1295 among peptides expected to return to legal compounding status, but formal FDA action is pending.

Where it stands now: CJC-1295 is in regulatory limbo. It's no longer on the Category 2 restricted list, but it hasn't been added to Category 1 either. The Kennedy reclassification announcement has not yet been formally published. Until it is, CJC-1295's legal status for compounding remains unclear.[9][10]

WADA / USADA status

CJC-1295 is prohibited at all times under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). GHRH and all its analogs are explicitly listed as prohibited substances. Testing methods for detecting CJC-1295 in biological samples have been published.[6][11]

International status

CJC-1295 is not approved for clinical use in any country. ConjuChem Biotechnologies, the original developer, is defunct. No pharmaceutical company is currently pursuing clinical development of CJC-1295. The compound is available as a research chemical from online suppliers.

Developer status

ConjuChem Biotechnologies, which held the patents on the DAC technology and CJC-1295 formulation, no longer exists. Many patents have expired or been abandoned. There is no active pharmaceutical development program for CJC-1295 anywhere in the world.

How CJC-1295 compares

To put CJC-1295 in context, here's how it compares to sermorelin — the FDA-approved GHRH analog that is essentially CJC-1295's predecessor:

CJC-1295

Research compound · Not FDA-approved

Animal evidence55%
Human evidence25%
Safety data20%

Phase I data

Yes

Phase II/III

Halted

FDA status

Limbo

Developer

Defunct

Sermorelin (Geref)

Previously FDA-approved · Discontinued 2008

Animal evidence70%
Human evidence55%
Safety data60%

FDA approved

1997-2008

Indication

Pediatric GHD

Discontinued

Supply issues

Half-life

10-20 min

The comparison is instructive. Sermorelin is the native GHRH (1-29) fragment — essentially the unmodified version of what CJC-1295 was built from. Sermorelin earned FDA approval for pediatric growth hormone deficiency and was only discontinued due to supply chain issues, not safety concerns. CJC-1295 was designed to be a better sermorelin — longer-lasting, less frequent dosing — but its development was cut short before those advantages could be proven in clinical outcomes.

Related content

Guide

How to Reconstitute Peptides

A clear, safety-first guide to preparing lyophilized peptides. Essential reading if you're working with any injectable peptide.

News

FDA Peptide Categories Explained

How CJC-1295's regulatory category affects compounding access.

Tool

Half-Life and Accumulation Plotter

Visualize CJC-1295 DAC's extended half-life and accumulation pattern.

References

  1. [1]
    Jette L, Bhatt R, Bhatt DL, et al.. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology. 2005. 146(7):3052-3058 DOI PubMedAnimal study

    Foundational paper from ConjuChem describing the DAC technology and first identification of CJC-1295.

  2. [2]
    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt DL. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006. 91(3):799-805 DOI PubMedPilot study

    The primary Phase I study. Open-label dose-escalation in ~60 healthy adults. Demonstrates the pharmacologic activity of CJC-1295.

  3. [3]
    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt DL. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006. 91(12):4792-4797 DOI PubMedPilot study

    Companion Phase I study confirming that pulsatile GH secretion is preserved during sustained CJC-1295 exposure. Important for understanding physiologic implications.

  4. [4]
    Alba M, Fintini D, Sagace A, Koch P, Bhatt DL, Salvatori R. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006. 291(6):E1290-E1294 DOI PubMedAnimal study

    Demonstrates functional GHRH receptor agonism in vivo. GHRH knockout mice treated with CJC-1295 achieved normal growth.

  5. [5]
    Ionescu M, Frohman LA. “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth Horm IGF Res. 2009. 19(3):267-274 DOI PubMedPilot study

    Proteomic analysis of serum samples from 11 healthy men before and after CJC-1295 injection. Identifies potential biomarkers of GH/IGF-1 axis activation.

  6. [6]
    Henninge J, Pepaj M, Hullstein I, Hemmersbach P. “Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.” Drug Test Anal. 2010. 2(11-12):647-650 DOI PubMedCase report

    Anti-doping forensic identification of CJC-1295 in an unknown pharmaceutical preparation. Relevant to WADA prohibition.

  7. [7]
    ConjuChem Biotechnologies. “Phase II clinical trial of CJC-1295 in HIV-associated lipodystrophy (terminated after participant death).” 2006. Link

    Randomized, double-blind, placebo-controlled Phase II trial enrolling ~192 participants at sites in North and South America. Permanently halted after one death from myocardial infarction. No results published.

  8. [8]
    Aidsmap. “Lipodystrophy study halted after patient death.” 2006. Link

    News report providing details of the Phase II trial termination, including the attending physician's assessment that the death was due to underlying coronary artery disease.

  9. [9]
    U.S. Food and Drug Administration. “Certain bulk drug substances that may present significant safety risks under conditions of use in compounding.” 2024. Link

    CJC-1295 was removed from Category 2 in September 2024 after the nominator withdrew, but was NOT added to Category 1.

  10. [10]
    U.S. Food and Drug Administration. “PCAC review documents for CJC-1295 (FDA-2024-N-4777).” 2024. Link

    FDA briefing document for the Pharmacy Compounding Advisory Committee. Includes detailed review of CJC-1295 safety and regulatory history.

  11. [11]
    World Anti-Doping Agency. “2024 Prohibited List — S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics.” 2024. Link

    GHRH and all its analogs (including CJC-1295) are explicitly prohibited under Section S2 at all times.

Medical disclaimer

Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research and is intended for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. CJC-1295 is not FDA-approved for any indication. A participant died during a Phase II clinical trial of this compound. Always consult a qualified healthcare provider before making decisions about peptide therapy.